Comparison of carboplatin–paclitaxel to docetaxel–cisplatin-5–flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer

Neoadjuvant chemotherapy in geriatric head and neck cancers

“…Multiple single arm studies have shown a promising response rate of 60% to 80% with the 2-drug taxane and platinum regimen. [21][22][23][24] Even these response rates seem higher than the response rate seen in our study. This may be due to a predominant proportion of patients having laryngeal or oropharyngeal primary tumors in these studies compared to our study.…”

“…However, whether the TPF regimen is associated with a better response rate than the 2‐drug regimen of taxane and platinum is unknown. Multiple single arm studies have shown a promising response rate of 60% to 80% with the 2‐drug taxane and platinum regimen . Even these response rates seem higher than the response rate seen in our study.…”

Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer

“…Gemcitabine is a poly-ADP-ribose polymerase (PARP) inhibitor that could inhibit the proliferation of tumor cells by blocking PARP signaling. [43] Furthermore, gemcitabine can inhibit the growth of cancer cells by targeting particular factors. [44] A previous study indicated that FU had some toxicity and side effects that could cause body pain and endothelial tissue ulceration; at the same time, its characteristic long-term onset time makes it easier for patients to develop drug resistance.…”

Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma

“…Consequently, extensive efforts are ongoing to identify alternative schemes that are less toxic than but as effective as the TPF regimen for locally advanced HNSCC and safely allow the use of definitive concurrent treatment based on cisplatin and radiotherapy …”